NOP2 Antibody

What is NOP2 and why is it an important research target?

NOP2, also known as NOL1, p120, NOP120, or nucleolar protein 1, is an 812 amino acid nucleolar protein that plays a crucial role in ribosome assembly and maintaining the structural integrity of the nucleolus. As a member of the methyltransferase superfamily, NOP2 functions as a ribosomal RNA methyltransferase essential for proper processing and maturation of rRNA, thereby influencing ribosome biogenesis and cellular proliferation. NOP2 links ribosome production to cell growth and division, making it a potential marker for proliferation in neoplastic cells and various cancer types. Additionally, NOP2 exhibits two isoforms resulting from alternative splicing events, which adds complexity to its regulatory roles in cellular processes . Research targeting NOP2 is particularly valuable for understanding fundamental cellular mechanisms and identifying novel therapeutic targets in cancer biology.

What are the standard applications for NOP2 antibodies in research?

NOP2 antibodies are versatile tools employed across multiple experimental approaches. Standard applications include western blotting (WB) at dilutions typically around 1:1000, immunoprecipitation (IP) generally at 1:50 dilution, immunofluorescence (IF) for cellular localization studies, and enzyme-linked immunosorbent assay (ELISA) for quantitative analysis . These antibodies enable researchers to detect NOP2 across multiple species including human, mouse and rat samples, allowing for comparative studies across model organisms. For optimal results in protein interaction studies, immunoprecipitation using NOP2 antibodies can effectively isolate NOP2 and its binding partners from cellular lysates, providing insights into its functional networks and regulatory mechanisms.

How do I select the appropriate NOP2 antibody for my experiment?

Selection of an appropriate NOP2 antibody depends on several critical factors:

• Experimental application: For western blotting, antibodies validated specifically for WB should be selected, with appropriate dilution recommendations (typically 1:1000) . For immunoprecipitation, antibodies with demonstrated IP efficiency (usually used at 1:50) are essential .

• Species reactivity: Verify that the antibody recognizes NOP2 in your experimental species. Many commercial antibodies detect human NOP2, but cross-reactivity with mouse or rat should be confirmed if working with these models .

• Antibody format: NOP2 antibodies are available in both non-conjugated forms and conjugated variants including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates . Select conjugated formats when direct detection is preferred.

• Validation status: Priority should be given to antibodies with published validation data demonstrating specificity and sensitivity for detecting endogenous NOP2, with minimal cross-reactivity to related proteins.

• Clonality: Both monoclonal (e.g., E-7 clone) and polyclonal options are available. Monoclonal antibodies offer higher specificity for particular epitopes, while polyclonal antibodies may provide stronger signals by recognizing multiple epitopes .

What are the optimal protocols for immunohistochemistry using NOP2 antibodies?

For optimal immunohistochemistry (IHC) results with NOP2 antibodies, the following methodological approach is recommended based on published protocols:

• Sample preparation: Fixed tissue sections should be deparaffinized and rehydrated through xylene and graded ethanol series. For formalin-fixed paraffin-embedded (FFPE) tissues, heat-induced epitope retrieval using Citrate Antigen Retrieval Solution is crucial, typically performed for 7 minutes in boiling water .

• Blocking and peroxidase quenching: Eliminate endogenous peroxidase activity using 3% hydrogen peroxide solution, followed by blocking with 10% goat serum for one hour to reduce non-specific binding .

• Primary antibody incubation: Apply the NOP2 antibody at an optimized dilution (typically 1:300 for IHC) and incubate overnight at 4°C. Studies have successfully employed antibodies such as the anti-NOP2 antibody (10448-1-AP, Proteintech) at this dilution .

• Detection system: Utilize appropriate secondary antibodies conjugated to detection systems compatible with your visualization method. For chromogenic detection, HRP-conjugated secondary antibodies with DAB substrate are commonly employed.

• Optimization considerations: Antibody concentration, incubation time, and antigen retrieval conditions should be optimized for each specific tissue type and fixation method to balance signal strength with background minimization.

How can I troubleshoot weak or non-specific signals in Western blots using NOP2 antibodies?

When encountering issues with Western blotting using NOP2 antibodies, consider these troubleshooting approaches:

• Protein size verification: NOP2 appears at approximately 89-110 kDa on Western blots, with slight variations depending on post-translational modifications and the molecular weight standards used . Confirm you are examining the correct molecular weight range.

• Blocking optimization: Non-specific binding can be reduced by optimizing blocking conditions. Try alternative blocking agents (5% non-fat milk, 5% BSA) or increasing blocking time to reduce background.

• Antibody dilution adjustment: For weak signals, consider reducing the antibody dilution (e.g., from 1:1000 to 1:500) . Conversely, for high background, increase dilution or reduce incubation time.

• Sample preparation improvements: Ensure complete protein denaturation and use fresh protease inhibitors during lysis to prevent NOP2 degradation. Consider enriching nuclear fractions to concentrate NOP2, which is primarily a nucleolar protein.

• Signal enhancement techniques: For detection of low abundance NOP2, consider using high-sensitivity ECL substrates or signal amplification systems. Alternatively, immunoprecipitation prior to Western blotting can concentrate the target protein.

• Membrane optimization: PVDF membranes may provide better results than nitrocellulose for NOP2 detection due to higher protein binding capacity.

How can NOP2 antibodies be utilized in cancer research studies?

NOP2 antibodies serve as valuable tools in cancer research due to NOP2's significant upregulation in various malignancies, including hepatocellular carcinoma (HCC), high-grade serous ovarian carcinoma (HGSOC), colorectal, and lung cancer . Implementation strategies include:

• Biomarker analysis: NOP2 antibodies can be employed for tissue microarray analysis to evaluate NOP2 expression across tumor cohorts, correlating expression with clinicopathological features and patient outcomes. Studies have demonstrated significant upregulation of NOP2 in HGSOC tissues compared to normal fimbria tissues, establishing NOP2 as a potential diagnostic marker .

• Functional studies: In cellular models, NOP2 antibodies enable monitoring of protein levels following genetic manipulation (knockdown, knockout, or overexpression). Research has shown that NOP2 knockdown inhibits proliferation, colony formation, migration, and invasion while increasing apoptosis in HCC cells, suggesting its pro-tumorigenic role .

• Mechanistic investigations: NOP2 antibodies facilitate the elucidation of molecular mechanisms underlying cancer progression. For instance, NOP2 may contribute to tumorigenesis by recruiting telomerase to the cyclin D1 promoter and activating gene expression. Additionally, NOP2 interacts with BRD4 and RNA polymerase II, suggesting roles in transcriptional regulation .

• Therapeutic response monitoring: Following treatment with experimental compounds, NOP2 antibodies can track changes in expression or localization, potentially serving as pharmacodynamic markers.

What approaches can be used to study NOP2's RNA methyltransferase activity?

Investigating NOP2's function as an RNA methyltransferase requires specialized experimental approaches where NOP2 antibodies play a critical role:

• RNA m5C dot blotting assay: This technique allows for detection of 5-methylcytosine (m5C) modifications in RNA. After extracting RNA from cells with modified NOP2 expression (overexpression or knockdown), the RNA is denatured, applied to nylon membranes in concentration gradients, cross-linked, and probed with anti-m5C antibodies. This approach enables quantitative assessment of how NOP2 manipulation affects global RNA methylation levels .

• RNA immunoprecipitation followed by sequencing (RIP-seq): NOP2 antibodies can be used to immunoprecipitate NOP2-bound RNA complexes, followed by high-throughput sequencing to identify specific RNA targets. This approach reveals the RNA substrate specificity of NOP2's methyltransferase activity.

• Methyltransferase activity assays: In vitro assays utilizing purified NOP2 (immunoprecipitated using NOP2 antibodies) can be employed to directly measure enzymatic activity. These assays typically involve incubating NOP2 with potential RNA substrates and S-adenosyl-L-methionine (SAM) as the methyl donor, followed by detection of methyl group transfer.

• Site-specific methylation analysis: After identifying potential target sites, methylation can be confirmed using techniques such as bisulfite sequencing adapted for RNA or mass spectrometry to pinpoint the exact cytosine residues modified by NOP2, such as C4413 in 28S rRNA .

How can I design experiments to investigate NOP2's role in cell cycle regulation?

NOP2 is primarily expressed during the G1 phase of the cell cycle, peaking in early S phase, suggesting its importance in cell cycle progression . A comprehensive experimental design to investigate this role would include:

• Expression profiling across cell cycle phases: Synchronize cells at different cell cycle stages (using methods such as double thymidine block or serum starvation/stimulation) and analyze NOP2 protein levels using Western blotting with NOP2 antibodies. This establishes the precise temporal expression pattern relative to established cell cycle markers.

• Genetic manipulation and phenotypic analysis: Generate NOP2 knockdown, knockout, or overexpression cellular models using CRISPR/Cas9 or RNA interference approaches. Use flow cytometry with propidium iodide staining to assess cell cycle distribution changes following NOP2 modulation. Research has confirmed that NOP2 knockdown significantly increases cell cycle block in HCC cells .

• Interaction studies with cell cycle regulators: Employ co-immunoprecipitation with NOP2 antibodies followed by mass spectrometry or Western blotting to identify interactions between NOP2 and known cell cycle regulatory proteins.

• Rescue experiments: In NOP2-depleted cells showing cell cycle alterations, reintroduce wild-type or mutant NOP2 (lacking methyltransferase activity) to determine which functional domains are essential for its cell cycle regulatory effects.

• Downstream mechanism investigation: Analyze the expression of cell cycle-related proteins (cyclins, CDKs, p21, p27) following NOP2 modulation to identify the key pathways through which NOP2 exerts its effects on cell cycle progression.

How can NOP2 antibodies be employed in studying its role in ribosome biogenesis and stability?

NOP2's function in ribosome biogenesis and stability can be investigated using several antibody-dependent approaches:

• Nucleolar co-localization studies: Immunofluorescence using NOP2 antibodies in combination with markers for different nucleolar compartments (fibrillar centers, dense fibrillar component, granular component) can reveal the precise localization of NOP2 within the nucleolus during ribosome assembly .

• Ribosome profiling: Following NOP2 depletion or overexpression, analyze ribosome assembly using sucrose gradient centrifugation followed by Western blotting of gradient fractions with NOP2 antibodies and ribosomal protein markers to determine how NOP2 alterations affect ribosome assembly intermediate formation.

• Pre-rRNA processing analysis: Northern blotting or qRT-PCR analysis of rRNA precursors in cells with modified NOP2 expression can reveal specific processing steps affected by NOP2 activity, particularly since methylation of C4413 in 28S rRNA by NOP2 is thought to increase ribosome stability .

• Pulse-chase analysis: Radiolabeling of nascent rRNA with modified nucleosides followed by immunoprecipitation with NOP2 antibodies can track the kinetics of NOP2 association with rRNA during maturation.

• Structural studies: Cryo-EM analysis of ribosomes from cells with altered NOP2 expression may reveal structural changes resulting from altered methylation patterns, providing insights into how these modifications contribute to ribosome stability.

What are the current technical limitations of NOP2 antibodies and how might they be addressed?

Current technical limitations of NOP2 antibodies include:

• Epitope masking in certain contexts: NOP2's nucleolar localization and incorporation into large ribonucleoprotein complexes may obscure epitopes in certain experimental contexts. This can be addressed by:

  • Developing antibodies targeting multiple distinct epitopes across the NOP2 protein

  • Optimizing sample preparation with different fixation methods or epitope retrieval protocols

  • Using native versus denaturing conditions depending on the application

• Cross-reactivity with related methyltransferases: NOP2 belongs to the NSUN family of RNA methyltransferases, which share conserved catalytic domains . Improved specificity can be achieved through:

  • Rigorous validation against related family members

  • Developing antibodies targeting unique regions outside the conserved methyltransferase domain

  • Implementing additional controls in experimental designs, such as parallel analysis in NOP2 knockout samples

• Variable detection of NOP2 isoforms: The presence of alternative splice variants may complicate interpretation of results. Solutions include:

  • Developing isoform-specific antibodies targeting unique exon junctions

  • Using multiple antibodies targeting different regions to distinguish isoform expression

  • Complementing antibody-based detection with RNA analysis to profile isoform abundance

• Limited suitability for certain applications: Some commercially available antibodies may perform well in Western blotting but poorly in immunoprecipitation or immunohistochemistry. This can be addressed by:

  • Comprehensive validation across multiple applications

  • Development of application-specific antibody formats (e.g., recombinant antibodies with improved stability)

  • Optimization of protocols specifically for challenging applications

How can NOP2 antibodies contribute to understanding differential expression in cancer progression?

NOP2 antibodies are instrumental in elucidating the relationship between NOP2 expression and cancer progression through multiple approaches:

• Comparative tissue profiling: Immunohistochemical analysis using NOP2 antibodies can quantify expression differences between normal tissues, precancerous lesions, primary tumors, and metastatic sites. Research has already demonstrated significant upregulation of NOP2 in hepatocellular carcinoma and high-grade serous ovarian carcinoma compared to normal tissues .

• Correlation with prognostic indicators: NOP2 expression levels detected by immunohistochemistry can be correlated with clinical outcomes, treatment response, and established prognostic markers to evaluate its potential as a prognostic biomarker across cancer types.

• Multi-parameter analysis: Multiplexed immunofluorescence combining NOP2 antibodies with markers for proliferation, apoptosis, and cancer stem cells can reveal associations between NOP2 expression and specific cellular phenotypes within heterogeneous tumor tissues.

• In vivo models: Animal studies using xenograft models with NOP2 knockout or overexpression, as demonstrated in research showing that NOP2 knockout significantly slowed tumor growth in mice, provide valuable insights into NOP2's role in tumor progression . Antibodies enable confirmation of NOP2 status in these models.

• Mechanistic investigations in patient-derived models: Patient-derived xenografts or organoids with varying NOP2 expression levels (detected using NOP2 antibodies) can be used to study differential sensitivity to therapeutics, potentially identifying patient subgroups that might benefit from targeting NOP2-dependent pathways.

How can NOP2 antibodies be integrated with other research tools to study RNA methylation pathways?

Comprehensive investigation of RNA methylation pathways involving NOP2 requires integration of antibody-based approaches with complementary methodologies:

• Antibody-based RNA methylation mapping: Combining NOP2 antibodies with anti-m5C antibodies enables correlation between NOP2 binding sites and m5C modification locations. This approach involves:

  • RNA immunoprecipitation with NOP2 antibodies to isolate NOP2-bound transcripts

  • m5C antibody-based techniques like m5C-RIP or m5C dot blotting to identify methylated sites

  • Computational integration of these datasets to identify direct NOP2 targets

• CRISPR/Cas9-mediated genetic manipulation: Genetic ablation of NOP2 using CRISPR/Cas9, followed by antibody-based detection methods to confirm knockout efficiency, provides a clean system to assess the direct impact of NOP2 loss on RNA methylation landscapes .

• Mass spectrometry validation: While antibodies provide valuable localization and semi-quantitative data, mass spectrometry offers precise identification and quantification of m5C modifications. This combination provides both spatial information (from antibody studies) and exact molecular characterization.

• Transcriptome-wide m5C profiling: Techniques like bisulfite sequencing adapted for RNA (BS-seq) or methylation-sensitive RNA sequencing can be applied to cells with confirmed NOP2 expression changes (validated by antibodies) to globally map methylation changes dependent on NOP2 activity.

• Functional readout integration: Correlating NOP2-dependent RNA methylation (detected using antibody approaches) with functional outcomes such as RNA stability, translation efficiency, or structural changes provides mechanistic insights into the biological significance of these modifications.

What considerations are important when designing experiments to investigate NOP2's role in specific cancer types?

When investigating NOP2's role in specific cancer types, several critical considerations should guide experimental design:

• Baseline expression profiling: Prior to functional studies, establish NOP2 expression patterns across normal tissues, tumor tissues, and available cell line models using validated antibodies. Research has shown variable overexpression of NOP2 across different cancer types, including hepatocellular carcinoma, high-grade serous ovarian carcinoma, colorectal cancer, and lung cancer .

• Model selection: Choose cellular models that recapitulate the expression patterns observed in patient samples. Consider:

  • Cell lines with naturally high or low NOP2 expression for gain or loss of function studies

  • Patient-derived models to maintain heterogeneity and clinically relevant genetic backgrounds

  • Animal models with tissue-specific NOP2 modification to study in vivo progression

• Phenotypic assay relevance: Select assays relevant to the specific cancer hallmarks observed in the cancer type of interest:

  • For highly proliferative cancers: focus on cell cycle progression, colony formation, and apoptosis assays

  • For invasive/metastatic cancers: prioritize migration, invasion, and in vivo metastasis models

  • For metabolically distinct cancers: incorporate metabolism assays relevant to the cancer type (e.g., glycolysis measurements for HCC, as NOP2 promotes aerobic glycolysis in this context)

• Treatment response integration: Evaluate how NOP2 expression (detected using antibodies) correlates with response to standard therapies for the specific cancer type, potentially identifying NOP2 as a predictive biomarker.

• Clinical correlation strategy: Plan for translational studies correlating experimental findings with clinical parameters specific to the cancer type, such as particular staging systems, cancer subtype classifications, or treatment response criteria.

How can researchers address data reproducibility challenges when using NOP2 antibodies across different experimental systems?

Ensuring data reproducibility when using NOP2 antibodies across different experimental systems requires systematic approaches: